Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials-Reference-Cited by-同舟云学术

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials

Published:2018-12-26 Issue:12 Volume:13 Page:e0204099
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lewis Marilyn,Mori Julie,Toma Jonathan,Mosley Mike,Huang Wei,Simpson Paul,Mansfield Roy,Craig Charles^ORCID,van der Ryst Elna,Robertson David L.,Whitcomb Jeannette M.,Westby Mike

Funder

Pfizer

ViiV Healthcare

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference60 articles.

1. HIV: cell binding and entry;CB Wilen;Cold Spring Harb Perspect Med,2012

2. HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy;I Bon;J Med Virol,2015

3. HIV-1 tropism dynamics and phylogenetic analysis from longitudinal ultra-deep sequencing data of CCR5- and CXCR4-using variants;MM Sede;PloS One,2014

4. A new classification for HIV-1;EA Berger;Nature,1998

5. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies;A Singh;J Virol,2000

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hybrid Virtual Screening Approach to Predict Novel Natural Compounds against HIV-1 CCR5;The Journal of Physical Chemistry B;2024-07-17

2. Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope;Journal of Virology;2022-07-27

3. Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV;HIV Medicine;2022-03-16

4. Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc;Antiviral Chemistry and Chemotherapy;2021-01

5. V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens;Antiviral Chemistry and Chemotherapy;2021-01